A 10-year follow-up study found that partial meniscectomy did not improve symptoms or knee function when compared with sham ...
Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage ...
A major 10-year clinical trial is turning one of the world’s most common knee surgeries on its head. Researchers found that ...
GLP-1RAs significantly reduce major cardiovascular events, mortality, and other clinically significant complications in ...
Current Infectious Disease Society of America guidelines for the treatment of invasive candidiasis recommend a minimum ...
Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...
Experts are already treating addicted people with at-home neuromodulation devices to control cravings, and the future is ...
The ENO Breathe programme can improve HRQOL, breathlessness, anxiety, and respiratory symptoms in people with long COVID and ...
Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsTamara Thornton - Director of Finance, Treasury ...
Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced ...
In a study supported by the National Institute on Drug Abuse of the National Institutes of Health, Johns Hopkins Medicine ...
David Toro-Tobon and colleagues argue that “clinician in the loop” is shifting responsibility for AI safety from developers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results